Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study

References

• Tu C, He J, Qi L, et al. Emerging landscape of circular RNAs as biomarkers and pivotal regulators in osteosarcoma. J Cell Physiol. 2020;235(12):9037–9058. doi:10.1002/jcp.2975432452026
   PubMed Web of Science ®Google Scholar
• Gao SS, Wang YJ, Zhang GX, Zhang WT. Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: a meta-analysis. J Bone Oncol. 2020;23:100307. doi:10.1016/j.jbo.2020.10030732742918
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115(7):1531–1543. doi:10.1002/cncr.2412119197972
   PubMed Web of Science ®Google Scholar
• Lagmay JP, Krailo MD, Dang H, et al. Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through children’s cancer group, pediatric oncology group, and children’s oncology group: learning from the past to move forward. J Clin Oncol. 2016;34(25):3031–3038. doi:10.1200/jco.2015.65.538127400942
   PubMed Web of Science ®Google Scholar
• Pappo AS, Vassal G, Crowley JJ, et al. A Phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a sarcoma alliance for research through collaboration study. Cancer. 2014;120(16):2448–2456. doi:10.1002/cncr.2872824797726
   PubMed Web of Science ®Google Scholar
• Xu J, Xie L, Guo W. Neoadjuvant chemotherapy followed by delayed surgery: is it necessary for all patients with nonmetastatic high-grade pelvic osteosarcoma? Clin Orthop Relat Res. 2018;476(11):2177–2186. doi:10.1097/corr.000000000000038729912746
   PubMed Web of Science ®Google Scholar
• Eilber FR, Mirra JJ, Grant TT, Weisenburger T, Morton DL. Is amputation necessary for sarcomas? A seven-year experience with limb salvage. Ann Surg. 1980;192(4):431–438. doi:10.1097/00000658-198010000-000016932827
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop Relat Res. 1991;(270):8–14.
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41(18):2836–2845. doi:10.1016/j.ejca.2005.08.02616298125
   PubMed Web of Science ®Google Scholar
• Ferrari S, Meazza C, Palmerini E, et al. Nonmetastatic osteosarcoma of the extremity. neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma group study (ISG/OS-Oss). Tumori J. 2014;100(6):612–619. doi:10.1177/1778.19262
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790. doi:10.1200/jco.2002.20.3.77611821461
   PubMed Web of Science ®Google Scholar
• Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften. 1973;60(9):399–406. doi:10.1007/bf006235514203933
   PubMed Web of Science ®Google Scholar
• Xie L, Xu J, Dong S, et al. Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years. Cancer Manag Res. 2019;11:7183–7195. doi:10.2147/cmar.S21460431447583
   PubMed Web of Science ®Google Scholar
• Cullen JW, Jamroz BA, Stevens SL, et al. The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration, and prediction of necrosis. J Vasc Interv Radiol. 2005;16(8):1107–1119. doi:10.1097/01.Rvi.0000167856.31329.F816105923
   PubMed Web of Science ®Google Scholar
• Abe S, Nishimoto Y, Isu K, Ishii T, Goto T. Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis. Cancer Chemother Pharmacol. 2002;50(4):320–324. doi:10.1007/s00280-002-0501-z12357307
   PubMed Web of Science ®Google Scholar
• Fox E, Levin K, Zhu Y, et al. Pantoprazole, an inhibitor of the organic cation transporter 2, does not ameliorate cisplatin-related ototoxicity or nephrotoxicity in children and adolescents with newly diagnosed osteosarcoma treated with methotrexate, doxorubicin, and cisplatin. Oncologist. 2018;23(7):762–e79. doi:10.1634/theoncologist.2018-003729445029
   PubMed Web of Science ®Google Scholar
• van der Woude HJ, Bloem JL, Verstraete KL, Taminiau AH, Nooy MA, Hogendoorn PC. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol. 1995;165(3):593–598. doi:10.2214/ajr.165.3.76454767645476
   PubMed Web of Science ®Google Scholar
• Lai YC, Chang WC, Chen CB, et al. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. Acta Radiol. 2020;61(7):983–991. doi:10.1177/028418511988758831739675
   PubMed Web of Science ®Google Scholar
• Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0. Nagoya J Med Sci. 2018;80(2):183–197. doi:10.18999/nagjms.80.2.18329915436
   PubMed Web of Science ®Google Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–1408. doi:10.1016/s1470-2045(16)30214-527569442
   PubMed Web of Science ®Google Scholar
• Wang H, Tang X, Xie L, Dong S, Chen C, Guo W. Stop-flow pelvic chemoperfusion for the treatment of malignant pelvic bone tumors: a preliminary study. Orthop Surg. 2020;12(3):741–748. doi:10.1111/os.1266632243077
   PubMed Web of Science ®Google Scholar
• Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101(1):14–18.299812
   PubMed Web of Science ®Google Scholar
• Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5(8):1191–1198. doi:10.1200/jco.1987.5.8.11913114435
   PubMed Web of Science ®Google Scholar
• Callaghan CM, Seyedin SN, Mohiuddin IH, et al. The effect of concurrent stereotactic body radiation and anti-PD-1 therapy for recurrent metastatic sarcoma. Radiat Res. 2020;194(2):124–132. doi:10.1667/rade-20-0001732845986
   PubMed Web of Science ®Google Scholar
• Evans AE. The success and failure of multimodal therapy for cancer in children. Cancer. 1975;35(1):48–54. doi:10.1002/1097-0142(197501)35:1<48::aid-cncr2820350107>3.0.co;2-b162853
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50. doi:10.1080/14737140.2018.141393929210294
   PubMed Web of Science ®Google Scholar
• Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50. doi:10.1016/j.ejca.2018.11.02730685685
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang J, Zhao N, et al. Progress in the chemotherapeutic treatment of osteosarcoma. Oncol Lett. 2018;16(5):6228–6237. doi:10.3892/ol.2018.943430405759
   PubMed Web of Science ®Google Scholar
• Stephens FO. Induction chemotherapy: to downgrade aggressive cancers to improve curability by surgery and/or radiotherapy. Eur J Surg Oncol. 2001;27(7):672–688. doi:10.1053/ejso.2001.115811669597
   PubMed Web of Science ®Google Scholar
• Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66(8):1703–1710. doi:10.1002/1097-0142(19901015)66:8<1703::aid-cncr2820660809>3.0.co;2-v2208024
   PubMed Web of Science ®Google Scholar
• Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51(3):402–407. doi:10.1002/1097-0142(19830201)51:3<402::aid-cncr2820510308>3.0.co;2-p6571796
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27(1):98–104. doi:10.1053/ejso.2000.105611237499
   PubMed Web of Science ®Google Scholar
• Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85(6):458–464. doi:10.1177/03008916990850060710774566
   PubMed Web of Science ®Google Scholar
• Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(8):893–899. doi:10.1023/a:10083911031329789613
   PubMed Web of Science ®Google Scholar
• Rha SY, Chung HC, Gong SJ, et al. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Oncol Rep. 1999;6(3):631–637. doi:10.3892/or.6.3.63110203605
   PubMed Web of Science ®Google Scholar
• Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat Res. 2005;&NA;(438):128–136. doi:10.1097/01.blo.0000179736.10871.76
   Web of Science ®Google Scholar
• Wilkins RM, Cullen JW, Odom L, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10(5):498–507. doi:10.1245/aso.2003.03.06112794015
   PubMed Web of Science ®Google Scholar
• van Houdt WJ, Griffin AM, Wunder JS, Ferguson PC. Oncologic outcome and quality of life after hindquarter amputation for sarcoma: is it worth it? Ann Surg Oncol. 2018;25(2):378–386. doi:10.1245/s10434-017-5806-628321692
   PubMed Web of Science ®Google Scholar
• Song WS, Cho WH, Jeon DG, et al. Pelvis and extremity osteosarcoma with similar tumor volume have an equivalent survival. J Surg Oncol. 2010;101(7):611–617. doi:10.1002/jso.2154020461769
   PubMed Web of Science ®Google Scholar
• Liu C, Xi Y, Li M, et al. Monitoring response to neoadjuvant chemotherapy of primary osteosarcoma using diffusion kurtosis magnetic resonance imaging: initial findings. Korean J Radiol. 2019;20(5):801–811. doi:10.3348/kjr.2018.045330993931
   PubMed Web of Science ®Google Scholar
• Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20(2):426–433. doi:10.1200/jco.2002.20.2.42611786570
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–1501. doi:10.1016/s1470-2045(17)30624-128988646
   PubMed Web of Science ®Google Scholar
• Fahey M, Spanier SS, Vander Griend RA. Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients. J Bone Joint Surg Am. 1992;74(3):321–330. doi:10.2106/00004623-199274030-000021548258
   PubMed Web of Science ®Google Scholar
• Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175(3):791–796. doi:10.1148/radiology.175.3.21883002188300
   PubMed Web of Science ®Google Scholar
• Torricelli P, Montanari N, Spina V, et al. Dynamic contrast enhanced magnetic resonance imaging subtraction in evaluating osteosarcoma response to chemotherapy. Radiol Med. 2001;101(3):145–151.11402952
   PubMedGoogle Scholar
• Kubo T, Furuta T, Johan MP, Adachi N, Ochi M. Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. Skeletal Radiol. 2016;45(9):1235–1242. doi:10.1007/s00256-016-2410-y27229874
   PubMed Web of Science ®Google Scholar